Investigational drug · Phase 3
FUB523
Also called: zigakibart, BION-1301, BION-1301 Single Dose, BION-1301 Multiple Doses
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
5 still active
All registered trials
6
Any phase or sponsor naming "FUB523"
First trial start
2019
Apr 8, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FUB523", any sponsor or status.
Conditions studied
As listed on its trial records.
- IgA Nephropathy
- Immunoglobulin A Nephropathy
- IgA Nephropathy (IgAN)
- Immunoglobulin A Nephropathy (IgAN)
- Kidney Diseases
- Kidney Diseases, Chronic
- Urological Diseases
- Glomerulonephritis
- Glomerular Disease
- Glomerulonephritis, IGA
Approved drugs for the same conditions: IgA nephropathy · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "FUB523" as an intervention, largest first.
- Atrasentan in Patients With IgA NephropathyPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04573478 · 404 participants · Start Dec 11, 2020 · Primary completion Apr 14, 2028
Drug: Atrasentan; Placebo and 1 more · For: IgA Nephropathy; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Alhambra, California; Glendale, California · 135 sites in all
- A Study of Zigakibart in Adults With IgA NephropathyPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05852938 · 383 participants · Start Jul 6, 2023 · Primary completion Aug 10, 2027
Drug: BION-1301; Placebo · For: IgA Nephropathy; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Huntsville, Alabama; San Francisco, California · 200 sites in all
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07850752 · 340 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 17, 2028
Drug: zigakibart; atrasentan and 1 more · For: IgA Nephropathy (IgAN)
Sites: Huntsville, Alabama; Fremont, California; Newark, Delaware · 11 sites in all
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06858319 · 220 participants (planned) · Start Jul 28, 2025 · Primary completion Jun 25, 2031
Drug: zigakibart · For: Kidney Diseases; Kidney Diseases, Chronic; Urological Diseases and 5 more
Sites: Denver, Colorado; Orlando, Florida; Iowa City, Iowa · 26 sites in all
- Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03945318 · 103 participants · Start Apr 8, 2019 · Primary completion Jun 10, 2026
Drug: BION-1301 Single Dose; Placebo Single Dose and 3 more · For: IgA Nephropathy
Sites: Northridge, California; Denver, Colorado; Orlando, Florida · 16 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07146906 · 32 participants (planned) · Start Mar 26, 2026 · Primary completion Jul 12, 2030
Drug: zigakibart · For: Immunoglobulin A Nephropathy (IgAN)
Sites: San Francisco, California; Denver, Colorado; Acworth, Georgia · 30 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting the B-Cell Activating Factor and a Proliferation-Inducing Ligand Pathway in IgAN: From Disease Pathogenesis to Clinical Trial Evidence.
Vasquez-Rios G, Rajasekaran A, Coca SG, et al. · Kidney Int Rep 2026
- Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes.
Dulos J, Kreijtz J, Vink P, et al. · Kidney Int Rep 2026
- Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy.
Kooienga L, Lo J, Lee EY, et al. · Kidney Int 2025
- The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy.
Yeo SC, Barratt J · Clin Kidney J 2023
- A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).
Williams CEC, Lamond M, Marro J, et al. · Clin Rheumatol 2023
Also in development for IgA Nephropathy
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- JADE101Phase 32 trials
Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy
- BHV-1400Phase 31 trial
Biohaven Therapeutics Ltd. · IgA Nephropathy
- NM8074Phase 28 trials
NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria
- XH-S003Phase 22 trials
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy
- ADX-097Phase 21 trial
Akebia Therapeutics · IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- CM338Phase 21 trial
Keymed Biosciences Co.Ltd · IgA Nephropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.